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ABSTRACT
Results of a previous phase I study suggested that a single 3 mg/m2 dose of the humanized non–FcR-binding
anti-CD3 monoclonal antibody visilizumab (Nuvion) was well tolerated and had efficacy for the treatment of
steroid-refractory acute graft-versus-host disease (GVHD). We now report results of a multicenter phase II
study in which visilizumab was given to 44 participants with steroid-refractory acute GVHD. Eighty-two
percent of the participants had visceral involvement, and 86% had overall grade III or IV acute GVHD at study
entry. The respective complete and overall response rates were 14% and 32% at 42 days. Plasma Epstein-Barr
virus DNA increased to more than 1000 copies per milliliter in 19 subjects. Seventeen received rituximab, and
no fatal lymphoproliferative disorders were observed. Survival at 180 days was 32% (95% confidence interval,
18%-46%). The administration of visilizumab as used in this study seems to be sufficiently safe and effective
to warrant further assessment for treatment or prevention of GVHD.
© 2005 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
Manifestations of acute graft-versus-host disease
aGVHD) persist despite primary therapy with glu-
ocorticoids in at least 50% of hematopoietic cell
ransplant (HCT) recipients [1,2]. There is no consis-
ently effective therapy for patients with steroid-re-
ractory (SR)–aGVHD, and survival has been poor
P.J. Martin, unpublished data, 2000) [3-6].
isilizumab (Nuvion; Protein Design Labs, Ply-
outh, MN) is a humanized, anti-CD3 monoclonal
ntibody characterized by a mutated immunoglobulin
2 isotype, a lack of binding to Fc receptors, and the
bility to induce apoptosis selectively in activated T a
B&MTells as a result of binding to CD3 [7-9]. Results of a
hase I study suggested that visilizumab was well tol-
rated in patients with SR-aGVHD, and improve-
ent was documented in 10 of 11 patients who re-
eived a single dose of visilizumab 3 mg/m2 [10]. The
ain complication was an increased risk of Epstein-
arr virus (EBV)–associated lymphoproliferative dis-
ase (LPD) that was prevented by monitoring plasma
BV DNA titers and preemptively administering rit-
ximab (IDEC, San Diego, CA). To conﬁrm the
afety and efﬁcacy of visilizumab and preemptive ad-
inistration of rituximab, we conducted a single-arm,
ulticenter phase II study in patients with SR-
GVHD.
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4ATIENTS AND METHODS
The study was approved by the Food and Drug
dministration and by the institutional review boards
t 9 participating centers. The primary goal was to
emonstrate that survival at 180 days after adminis-
ration of visilizumab exceeded 20%, on the basis of
xperience that the survival of patients with SR graft-
ersus-host disease (GVHD) after treatment with an-
ithymocyte globulin is less than 20% (P.J. Martin,
npublished data, 2000) [3-5]. The target accrual of
0 subjects was based on the assumption that the true
ate of EBV LPD is 1% to 2% and on the need to have
0% power to be 80% conﬁdent that the true rate of
atal EBV LPD was less than 5%. On the basis of the
ssumption that the true 180-day survival after visili-
umab was 35%, this sample size provided 90% power
o determine with 95% conﬁdence that the true 180-
ay survival rate after the administration of visili-
umab exceeded 20% (95% conﬁdence interval [CI],
1%-41%). Prespeciﬁed secondary end points in-
luded pharmacokinetics, weekly response to visili-
umab through 42 days, numeric T-cell recovery,
lasma EBV and human herpesvirus 6 (HHV6) viral
oads, and the incidence of EBV LPD after preemp-
ive administration of rituximab whenever plasma
BV DNA exceeded 1000 copies per milliliter.
Patients were eligible if they were within 100 days
fter HCT and had grade II to IV aGVHD progress-
ng after 3 days, nonimproving grade III to IV
GVHD persisting after 7 days, or nonimproving
rade II aGVHD persisting after 14 days of methyl-
rednisolone 2 mg/kg/d [10]. A biopsy sample taken
rom the gastrointestinal tract, skin, or liver was re-
uired to conﬁrm the diagnosis of GVHD. Patients
ere excluded if they had received anti–T-cell mono-
lonal antibodies during the preceding 30 days or
ntithymocyte globulin during the preceding 90 days;
f they required mechanical ventilatory support; if they
ad had prior splenectomy, recurrent or secondary
alignancy, uncontrolled infection, or confusion; or if
hey were older than 12 years and scored less than 24
f 30 in the standardized Mini-Mental State Exami-
ation of cognitive status [11,12].
Consenting subjects continued to receive treat-
ent with a calcineurin inhibitor and methylpred-
isolone and were given a single dose of visilizumab
mg/m2 intravenously. If aGVHD recurred after 2
eeks but no more than 6 weeks after a documented
esponse to the ﬁrst dose of visilizumab, a second dose
f visilizumab could be administered, provided that
he study participants satisﬁed the original deﬁnitions
f SR-aGVHD and that they understood and again
igned informed consent. The administration of
ethylprednisolone was continued for at least 7 days
t 2 mg/kg/d, and doses were then tapered by
.2 mg/kg every 5 days as tolerated. Acute GVHD in p
66he skin, liver, and gastrointestinal tract was staged 1
hrough 4 according to modiﬁed criteria based on the
chema of Glucksberg et al. [13], and GVHD was also
raded I through IV according to the overall sever-
ty [1]. Responses after the administration of visili-
umab were scored on days 4, 7, 14, 21, 28, 35, 42, 90,
nd 180 and were deﬁned as follows: complete re-
ponse, the resolution of GVHD in all evaluable or-
ans with no subsequent additional treatment given
or aGVHD; partial response, the improvement of at
east 1 evaluable organ without deterioration in at
east 1 other; stable disease, no signiﬁcant change in
ny organ system; progressive disease, deterioration in
t least 1 evaluable organ; or not evaluable, organ
omplications other than GVHD exist or otherwise
nable to determine response. Visilizumab pharmaco-
inetics and immunogenicity and T-lymphocyte
ounts were measured as described [10]. Plasma viral
oads were quantiﬁed at baseline and then weekly for
HV6 and twice weekly for EBV until 42 days after
he administration of visilizumab by using real-time
olymerase chain reaction techniques [10]. Rituximab
75 mg/m2 intravenously was administered when
lasma EBV DNA exceeded 1000 copies per milliliter.
hree additional weekly doses were given if subse-
uent EBV DNA levels exceeded 1000 copies per
illiliter. Appropriate infection prophylaxis or treat-
ent for cytomegalovirus (CMV), herpes simplex vi-
us, varicella-zoster virus, Pneumocystis jiroveci, can-
ida, and invasive molds was recommended according
o standard practice at each study site. The protocol
peciﬁed ganciclovir or foscarnet therapy when
HV6 DNA was present in the cerebrospinal ﬂuid of
ubjects who developed confusion or other signs of
ncephalitis or a progressive increase in plasma
HV6 DNA after the administration of visilizumab.
Survival curves were estimated by using the
aplan-Meier method. Hazard ratios were estimated
y univariate analysis with Cox proportional hazard
odels.
ESULTS
tudy Participants and Accrual
Between April 2002 and April 2003, 44 subjects
ere entered onto the study, and their characteristics
efore the administration of visilizumab are described
n Tables 1 and 2. Although no protocol-deﬁned end
oints had been met, the sponsor exercised the right
o close the study to further enrollment before the
lanned accrual of 80 participants was reached. Nearly
wo thirds of the participants had received a myeloa-
lative preparative regimen, and the remainder had
eceived a reduced-intensity preparative regimen.
ight subjects were younger than 17 years. Eighty
ercent of subjects received methotrexate and either
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Treatment of GVHD with Humanized CD3-Specific Antibody
Byclosporine or tacrolimus as part of GVHD prophy-
axis. Six subjects received mycophenolate mofetil
ather than methotrexate as part of GVHD prophy-
axis. Fourteen (32%) had been receiving treatment
or GVHD with mycophenolate mofetil in addition to
calcineurin inhibitor and methylprednisolone when
isilizumab was given.
Most participants had severe visceral GVHD. At
he time of enrollment, 86% had grade III or IV
VHD, 68% had gastrointestinal stage 3 or 4 in-
olvement, and 32% had a serum total bilirubin con-
entration of 3 mg/dL. Forty-two participants re-
eived a single dose of visilizumab, and 2 received
econd doses of visilizumab at 18 and 49 days after
able 1. Characteristics of the 44 Subjects before Administration of
isilizumab
Characteristic Data
edian age, y (range) 43 (3-69)
ale/female 28/16
iagnosis
Acute leukemia/myelodysplastic syndrome 30
Chronic myeloid leukemia/myeloproliferative
disorder 5
Lymphoma 6
Other (myeloma, immune deficiency
disorder, CLL) 3
reparative regimen
Myeloablative, TBI-based 13
Myeloablative, chemotherapy-based 15
Nonmyeloablative or reduced intensity 16
tem cell source
Bone marrow 13
Peripheral blood stem cells 30
Cord blood 1
onors
Antigen matched related 17
Allele matched unrelated 13
Single class I allele mismatched unrelated 1
Single class I antigen mismatched unrelated 8
Multiple allele and/or antigen mismatched
unrelated 5
ays from transplantation to onset of GVHD,
median (range) 23 (6-106)
VHD prophylaxis
Cyclosporine/methotrexate 25
Cyclosporine/mycophenolate mofetil 5
Cyclosporine/methylprednisolone 1
Tacrolimus/methotrexate 10
Tacrolimus/mycophenolate mofetil 3
edian days of methylprednisolone therapy
(range) 11 (13-92)
VHD treatment (within 3 wk of enrollment)
Mycophenolate mofetil with or without
tacrolimus 14
Sirolimus 1
ays from transplantation to enrollment
(range) 40 (15-119)
ata are number of patients unless otherwise marked.
LL indicates chronic lymphocytic leukemia; TBI, total body ir-
radiation.artial response to the ﬁrst dose. G
B&MTurvival and Response
Survival among the 44 study participants was 32%
95% CI, 18%-46%) at 180 days (Figure 1A). Nine
emain alive at 310 to 724 days (median, 539 days),
nd 35 have died at a median of 30 days (range, 4-372
ays) as a result of GVHD (n  13), infection (n  8),
ultiorgan failure (n  7), recurrent malignancy (n 
), myocardial infarction (n  1), fatal arrhythmia
n  1), and hemorrhagic pancreatitis (n  1). Organ-
sms that caused fatal infections included molds or
andida (n  4), bacteria (n  5), CMV (n  3),
erpes simplex virus (n  1), parainﬂuenza virus (n 
), and inﬂuenza virus (n  1). Mortality was higher
mong the 25 subjects with serum bilirubin concen-
rations 3 mg/dL or with GVHD that was treated
ith mycophenolate mofetil before visilizumab ad-
inistration than among the 19 subjects who had
either of these risk factors (hazard ratio, 2.5; 95% CI,
.2-5.0; Figure 1B).
At day 42, the complete and overall response rates
ere 14% and 32%, respectively, among all patients
ho were treated with visilizumab (Figure 2A) and
7% and 73%, respectively, among patients who were
till alive at day 42 (data not shown). Complete and
verall responses occurred less frequently among sub-
ects with serum bilirubin concentrations 3 mg/dL
r with GVHD that was treated with mycophenolate
ofetil before enrollment (Figure 2B) than among
hose with neither of these risk factors (Figure 2C).
harmacokinetics and Pharmacodynamics
Mean serum concentrations of visilizumab among
he 43 subjects who could be evaluated are shown in
igure 3A (left). The antibody Cmax (mean  SEM) at
hour was 1550  71 ng/mL. The terminal elimina-
ion half-life (mean  SEM) was 111  19 hours, and
he mean serum clearance was 0.03  0.003 L/m2/h.
or comparison, the mean serum concentrations of
isilizumab are also shown for the group of subjects in
he phase I study who received the identical dose
egimen [10] (Figure 3A, right). The median T-cell
ount in the blood was 200/L (range, 45-1956/L)
able 2. Severity of GVHD before Administration of Visilizumab
Organ
Stage and Grade of GVHD
0 I II III IV
kin 18 8 4 11 3
iver 18 12 6 5 3
I 10 0 4 12 18
verall 0 0 6 15 23
he number of patients with the following symptoms of GVHD
included 26 (59%) with rash, 26 (59%) with serum bilirubin
2.0 mg/dL, 8 (18%) with serum bilirubin 6.0 mg/dL, and 34
(77%) with diarrhea.I indicates gastrointestinal.
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4efore the administration of visilizumab and decreased
o 37/L (range, 3-467/L) afterward (Figure 3B).
rug-Related Toxicities, Immunogenicity, and
iral Reactivation
Nineteen (41%) of 46 visilizumab infusions were
ollowed by transient grade 1 to 2 (grade 3 in 2
ubjects) symptoms, including fever, chills, tachycar-
ia, hypotension, and pain. There were no allergic
eactions. No human antibodies against visilizumab
ere detected in any of the 21 participants who sur-
ived until day 42 or in any of the 16 participants who
urvived until day 90 after the administration of visili-
umab.
Plasma EBV DNA was not detectable before the
dministration of visilizumab in 40 subjects. After the
igure 1. Kaplan-Meier probability of overall survival after the adm
eparately for subjects with serum bilirubin 3 mg/dL or with GVH
urve; n  25) and for subjects who had neither of these risk facto
f 15 subjects treated with mycophenolate mofetil before enrollme
igure 2. GVHD response after the administration of visilizumab.
stippled bars) responses to visilizumab at weekly time points for all
eing treated with mycophenolate mofetil (B), and for subjects w
ycophenolate mofetil (C). The number of patients evaluated for each re
68dministration of visilizumab, plasma EBV DNA ex-
eeded 1000 copies per milliliter in 19 (43%) subjects,
nd this prompted administration of a single dose of
ituximab in 7 subjects and multiple doses in 10. One
atient died from causes not related to EBV at 32 days
fter receipt of visilizumab, on the ﬁrst day that the
lasma EBV DNA exceeded 1000 copies per milliliter
nd before receiving rituximab. The remaining patient
ad a single plasma EBV DNA level of 1200 copies
er milliliter and did not receive rituximab but had
pontaneous resolution of EBV viremia. Two months
fter the administration of visilizumab, 1 subject de-
eloped an enlarged cervical lymph node with histo-
ogically conﬁrmed EBV LPD that resolved after 2
oses of rituximab. Shown in Figure 4 is the cumula-
ive probability of remaining alive without EBV reac-
tion of visilizumab. A, All study participants. B, Survival is shown
t was treated with mycophenolate mofetil before enrollment (lower
er curve; n  19). Survival more than 100 days was observed in 2
2 of 14 subjects with serum bilirubin 3 mg/dL.
are the percentages of patients with complete (solid bars) or partial
s (A), for subjects who had serum bilirubin 3 mg/dL or who were
erum bilirubin was 3 mg/dL and were not being treated withinistra
D tha
rs (uppShown
subject
hose ssponse is indicated above each bar for each time point.
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Treatment of GVHD with Humanized CD3-Specific Antibody
Bivation among subjects enrolled in this study and
mong subjects treated with an identical dose of vi-
ilizumab in the earlier phase I study.
Although there were more early deaths and there
as inferior overall survival among participants in the
hase II study than among those who received an
dentical dose of visilizumab in the phase I study, EBV
eactivation occurred later (and less frequently; data
ot shown) in this study than in the prior study.
One subject died with disseminated fungal infec-
ion and encephalitis 13 days after treatment with
isilizumab. This patient had 110 000 copies per mil-
igure 3. Visilizumab pharmacokinetics and T-lymphocyte reco
isilizumab as measured by a biotinylated streptavidin (SA)–horsera
ose of 3.0 mg/m2 on the phase II study (). Results are from day
3), day 2 (24 hours; n  42), and days 7 (n  42), 14 (n  33), 21 (
omparable phase I study data as measured by a nonbiotinylated SA-
-cell counts were 45 to 1956/L (median, 200/L). After the adm
f the antibody decreased. Absolute T-cell counts were 20 to 2209/
dministration of visilizumab in 17 subjects who could be evaluated
igure 4. Kaplan-Meier probability of survival without Epstein-
arr virus (EBV) reactivation. Shown is the probability of remain-
ng alive after a single 3 mg/m2 dose of visilizumab and without
evelopment of plasma EBV DNA levels 1000 copies per milli-
iter for subjects in the current study (solid line) compared withsubjects in the earlier phase I study (stippled line).
B&MTiliter of plasma HHV6 DNA before the administra-
ion of visilizumab and, presumably, had progressive
HV6 infection and encephalitis after administration
f the drug. Plasma HHV6 DNA exceeded 1000 cop-
es per milliliter in 26 other subjects, but this was not
ssociated with clinical adverse events.
ISCUSSION
Improvement in the manifestations of GVHD was
lower in the phase II study compared with the phase
study, and response rates were also substantially
ower in the phase II study than in the phase I study,
hich tested the same 3 mg/m2 dose regimen and also
lower, multiple-dose schedules [10]. In keeping with
hese observations, the median survival of 41 days for
ll subjects in the phase II study was less than the
edian of 300 days for those who received the same
ose in the phase I study. Differences between the
hase II and phase I study cohorts and potential dif-
erences between the drug lots used for each study
ight have contributed to the variation in GVHD
esponse rates and survival.
In the phase II study, 86% of subjects had grade
II to IV GVHD, 68% had gastrointestinal stage 3 or
involvement, and 32% had a serum bilirubin con-
entration 3 mg/dL at enrollment, compared with
1%, 82%, and 16%, respectively, among subjects
ho received visilizumab 3 mg/m2 in the phase I
, The left panel shows mean  SEM serum concentrations of
roxidase (HRP) assay for 43 evaluable subjects treated with a single
hin 30 minutes before dosing and 1 and 4 hours after dosing; n 
), 28 (n  20), 35 (n  20), and 42 (n  20). The right panel shows
ssay (□). [10] B, Before the administration of visilizumab, absolute
ion of visilizumab, absolute T-cell counts increased as serum levels
dian, 256/L) at a median of 21 days (range, 14-90 days) after thevery. A
dish pe
1 (wit
n  28
HRP a
inistrat
L (metudy. Hepatic GVHD might have been more severe
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4mong subjects in the phase II study than among those
n the phase I study. In other respects, however, sub-
ects in the phase II study did not seem to have more
evere GVHD than those in the phase I study. The
edian age of subjects was 43 years in the phase II
tudy, compared with 24 years in the phase I study.
he median duration of methylprednisolone therapy
efore enrollment was 11 days (range, 3-92 days) in
he phase II study, compared with 15 days (range, 5-50
ays) among subjects who received visilizumab 3
g/m2 in the phase I study. However, 14 (32%) sub-
ects in the phase II study had received mycophenolate
ofetil for treatment of GVHD before enrollment,
nd their survival was inferior to the survival of sub-
ects who had not been treated with mycophenolate
ofetil. Thus, these subjects received visilizumab as a
hird-line intervention, rather than a second-line in-
ervention, as intended. In the phase I study, all sub-
ects received visilizumab as a second-line interven-
ion.
The antibody Cmax at 1 hour was 30% lower in the
hase II study compared with the phase I study
Figure 3A), and the antibody was also cleared more
uickly from the circulation [10]. During the compar-
son of the phase II pharmacokinetic data with the
hase I data, the authors (P.A.C. and J.S.M.) discov-
red that the reported mean clearance of 6.99  1.23
/m2/h had been incorrectly calculated in the phase I
tudy. The mean clearance in the phase I study was
ecalculated at 0.012  0.002 L/m2/h, and the deri-
ation was validated by the collaborating pharmacol-
gists who were involved in the current study (J.S.M.)
nd the previous study (J. Slattery, Fred Hutchinson
ancer Research Center and University of Washing-
on, Seattle, WA) [10]. Accordingly, the mean clear-
nce of visilizumab in the phase II study (0.03 0.003
/m2/h) was 2.5-fold faster, and the terminal elimina-
ion half-life (111  19 hours) was 30% shorter com-
ared with those in the phase I study.
The absolute peripheral blood T-cell counts were
igher after the administration of visilizumab in the
hase II study (median, 37/L; range, 3-467/L)
ompared with the phase I study (median, 6/L;
ange, 1-17/L). In keeping with this observation, a
ower proportion of subjects had an increase in plasma
BV DNA to 1000 copies per milliliter during the
rst 3 weeks after administration of visilizumab in the
hase II study than in the phase I study.
Different lots of visilizumab were used for the 2
tudies. The concentrations of the antibody lots were
mg/mL for the phase II study and 0.1 mg/mL for the
hase I study, but the stability of both lots seemed to
e the same, with minimal changes even in accelerated
esting (data not shown). The pharmacokinetic and
harmacodynamic differences remain to be explained.
In both studies, visilizumab infusions were gener-
lly well tolerated. The main complication after the t
70dministration of visilizumab is an increased risk of
iral infection, mostly resulting from reactivation of
atent herpesviruses such as HHV6, CMV, and EBV.
he risk period for latent herpesvirus reactivation
enerally begins before engraftment for HHV6
14,15] and continues after engraftment for CMV and
BV LPD [16,17]. In this study, we extended our
bservations from the phase I study showing that
eal-time measurement of plasma EBV DNA [10] and
reemptive administration of rituximab is an effective
trategy for preventing EBV LPD. Although this
trategy may expose recipients to unnecessary therapy,
18] our approach was based on observations that
vert EBV LPD can have a fulminant course and fatal
utcome after the administration of agents that de-
lete T cells in patients with SR-aGVHD after T
ell–replete HCT [10,17,19,20]. In the setting of T
ell–depleted HCT, the strategy of preemptive ritux-
mab based on real-time monitoring of the EBV DNA
iral load is also effective in preventing mortality from
BV LPD [21]. Antiviral prophylaxis will likely be
equired to prevent reactivation of HHV6 and CMV
f potent in vivo T cell–depleting agents such as vi-
ilizumab are used for prevention or earlier treatment
f aGVHD.
The 32% survival at 180 days among participants
ith SR-aGVHD in this study compares favorably to
esults with polyclonal antithymocyte globulins (P.J.
artin, unpublished data, 2000) [3-6] and to more
ontemporary results with novel humanized or chi-
eric monoclonal antibodies (Zain et al., unpublished
ata, 2005) [22-24] and recombinant fusion proteins
24]. Considerable room for improvement remains in
reventing and treating aGVHD after T cell–replete,
LA-mismatched, or unrelated HCT. Also on the
asis of our earlier in vitro studies showing that visili-
umab induces apoptosis selectively in activated hu-
an T cells, [9] we believe that the further evaluation
f selective depletion of activated T cells with the use
f visilizumab or similar reagents for the treatment or
revention of GVHD is warranted.
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